Table 1 |
|||
|
Characteristics for the AD group and the group of healthy elderly individuals |
|||
|
AD |
HC |
Group difference |
|
|
|
|||
|
Demographics |
|||
|
Number |
38 |
34 |
|
|
Age |
76 ± 7 |
77 ± 8 |
ns |
|
Gender (F/M) |
23/15 |
24/10 |
ns |
|
MMSE |
19 ± 5 |
29 ± 1 |
P < 10-12 |
|
APOE ε4 heterozygote (homozygote) |
63% (13%) |
24% (3%) |
P < 10-4 |
|
CSF** |
|||
|
Aβ42 |
307 ± 91 |
647 ± 166 |
P < 10-11 |
|
T-tau |
938 ± 542 |
399 ± 194 |
P < 10-8 |
|
P-tau |
106 ± 55* |
64 ± 28 |
P < 10-4 |
|
MMP-1 |
0.024 ± 0.016 |
0.021 ± 0.01 |
ns |
|
MMP-3 |
0.716 ± 0.35 |
0.700 ± 0.36 |
ns |
|
MMP-9 |
0.902 ± 0.39 |
0.859 ± 0.35 |
ns |
|
TIMP-1 |
0.035 ± 11.7 |
0.041 ± 13.0 |
P < 0.05 |
|
MMP-1/TIMP-1 |
0.697 ± 0.35 |
0.564 ± 0.25 |
ns |
|
MMP-3/TIMP-1 |
21.1 ± 9.7 |
18.1 ± 9.8 |
ns |
|
MMP-9/TIMP-1 |
26.9 ± 11.9 |
22.7 ± 11.8 |
P < 0.05 |
|
|
|||
|
Aβ42, β-amyloid1-42; AD, Alzheimer's disease; APOE, apolipoprotein E; CSF, cerebrospinal fluid; F, female; HC, healthy controls; M, male; MMP, matrix metalloproteinase; MMSE, mini mental state examination; TIMP, tissue inhibitor of metalloproteinase. * n = 28. ** Levels are in ng/l for Aβ42, T-tau and P-tau and in ng/ml for the MMPs and TIMP-1. |
|||
|
Stomrud et al. Alzheimer's Research & Therapy 2010 2:20 doi:10.1186/alzrt44 |
|||
